- Home
- CMPS vs EYPT Comparison
CMPS vs EYPT Comparison
Compare CMPS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPS
- EYPT
- Stock Information
- Founded
- CMPS 2020
- EYPT 1987
- Country
- CMPS United Kingdom
- EYPT United States
- Employees
- CMPS N/A
- EYPT N/A
- Industry
- CMPS Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- CMPS Health Care
- EYPT Industrials
- Exchange
- CMPS Nasdaq
- EYPT Nasdaq
- Market Cap
- CMPS 364.9M
- EYPT 390.0M
- IPO Year
- CMPS 2020
- EYPT 2005
- Fundamental
- Price
- CMPS $4.59
- EYPT $8.12
- Analyst Decision
- CMPS Strong Buy
- EYPT Strong Buy
- Analyst Count
- CMPS 7
- EYPT 8
- Target Price
- CMPS $18.83
- EYPT $24.29
- AVG Volume (30 Days)
- CMPS 1.1M
- EYPT 896.8K
- Earning Date
- CMPS 07-31-2025
- EYPT 05-07-2025
- Dividend Yield
- CMPS N/A
- EYPT N/A
- EPS Growth
- CMPS N/A
- EYPT N/A
- EPS
- CMPS N/A
- EYPT N/A
- Revenue
- CMPS N/A
- EYPT $56,042,000.00
- Revenue This Year
- CMPS N/A
- EYPT N/A
- Revenue Next Year
- CMPS N/A
- EYPT N/A
- P/E Ratio
- CMPS N/A
- EYPT N/A
- Revenue Growth
- CMPS N/A
- EYPT 12.04
- 52 Week Low
- CMPS $2.49
- EYPT $3.91
- 52 Week High
- CMPS $8.54
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- CMPS 64.81
- EYPT 71.92
- Support Level
- CMPS $3.86
- EYPT $5.46
- Resistance Level
- CMPS $4.52
- EYPT $7.44
- Average True Range (ATR)
- CMPS 0.36
- EYPT 0.59
- MACD
- CMPS 0.00
- EYPT 0.21
- Stochastic Oscillator
- CMPS 65.63
- EYPT 95.59
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.